Factors influencing sustainable efficacy of smoking cessation treatment with varenicline beyond nine months.

about

Factors influencing sustainable efficacy of smoking cessation treatment with varenicline beyond nine months.

Item

http://www.wikidata.org/entity/Q36948579

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Factors influencing sustainabl ...... arenicline beyond nine months.

@en

type

Item

label

Factors influencing sustainabl ...... arenicline beyond nine months.

@en

prefLabel

Factors influencing sustainabl ...... arenicline beyond nine months.

@en

P1476

Factors influencing sustainabl ...... arenicline beyond nine months.

@en

P2093

Mitsuo Sato

http://www.w3.org/2001/XMLSchema#string

Nobutaro Ban

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Hamajima

http://www.w3.org/2001/XMLSchema#string

Satoko Shimadu

http://www.w3.org/2001/XMLSchema#string

Tomoyo Oguri

http://www.w3.org/2001/XMLSchema#string

Toyoaki Murohara

http://www.w3.org/2001/XMLSchema#string

Yoshinori Hasegawa

http://www.w3.org/2001/XMLSchema#string

Yu Okada

http://www.w3.org/2001/XMLSchema#string

P2860

Change in mental health after smoking cessation: systematic review and meta-analysis

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

The English smoking treatment services: one-year outcomes.

Predictors of smoking cessation in a cohort of adult smokers followed for five years.

Smoking cessation and depression: current knowledge and future directions.

Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use.

Varenicline: a first-line treatment option for smoking cessation.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers.

P304

205-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27303107

http://www.w3.org/2001/XMLSchema#string

P932

4885820

http://www.w3.org/2001/XMLSchema#string